TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$4.07
0.00 (0.00%)
▲
5d:
-10.35%
30d:
-10.15%
90d:
-30.19%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 21, 2026
Smart Money Accumulation
TSHA is down 7.5% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 202 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $4.07, which is considered oversold relative to its 30-day fair value range of $4.34 to $4.72.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $4.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.29 (+177.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $4.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.29 (+177.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.34 -
$4.72
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 177.3% below Wall St target ($11.29)
- CAUTION: 5-day price weakness (-10.4%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$4.34 -
$4.72
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.03
Resistance Level
$4.66
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.85
Wall Street Target
$11.29
(+177.3%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: March 30, 2026 6:17 PM ET
Data refreshes hourly during market hours. Next update: 7:17 PM
Data refreshes hourly during market hours. Next update: 7:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Kamran Alam
SELL
1655 shares
2026-02-04
Kamran Alam
SELL
23849 shares
2026-01-26
Sean P Nolan
SELL
41312 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 48 HOLD |
